GRI Bio, Inc. 8-K

What Happened

• GRI Bio, Inc. announced a 1-for-28 reverse stock split of its common stock, effective 4:01 p.m. Eastern Time on January 23, 2026. Shares are expected to begin trading on a post-split basis at the open of Nasdaq on January 26, 2026 under the same ticker, GRI. The company filed a Certificate of Amendment with the Delaware Secretary of State to effect the split and issued a press release announcing the action.

Key Details

• Reverse ratio: 1-for-28 (every 28 issued and outstanding shares will convert into 1 share).
• Effective time: 4:01 p.m. ET on January 23, 2026; expected post-split trading begins Jan 26, 2026.
• Fractional shares: Holders entitled to fractional shares will receive a cash payment equal to the fractional share multiplied by the closing sale price on Nasdaq on Jan 23, 2026 (adjusted for the split).
• Other effects: No change to authorized shares or par value; proportionate adjustments will be made to exercise prices and share amounts for outstanding options, warrants, convertible securities, and equity incentive plans. New CUSIP after the split: 3622AW502.

Why It Matters

• For investors, the reverse split reduces the number of outstanding shares and increases the per-share figure proportionately (no change to a holder’s percentage ownership except for cash-outs of fractional shares).
• The filing confirms adjustments to stock options, warrants, convertibles and incentive-plan share amounts, so holders of those instruments should expect updated exercise prices and share totals.
• Trading will continue on Nasdaq under the same symbol (GRI) after the split; fractional-share cash payments will be based on the Jan 23, 2026 closing price as described in the filing.